Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy

Andrei Szigiato,Nitesh Mohan,Katherine E. Talcott,Danny A. Mammo,Amy S. Babiuch,Peter K. Kaiser,Justis P. Ehlers,Aleksandra Rachitskaya,Alex Yuan,Sunil K. Srivastava,Sumit Sharma

OPHTHALMOLOGY（2024）

引用 0|浏览13

暂无评分

摘要

Switching to faricimab resulted in a reduction in mean CST (-11.6um, p=0.01) and PED height (-44.2um, p=0.01) after 3 injections with stable VA and at a similar treatment interval to prior anti-VEGF therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要